Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · see citing works

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458 · see citing works

ggplot2

Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,612 · see citing works

Integrative genomics viewer

Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · see citing works

ggplot2: Elegant Graphics for Data Analysis

Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447 · see citing works

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688 · see citing works

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180 · see citing works

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053 · see citing works

<i>DNMT3A</i> Mutations in Acute Myeloid Leukemia

Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983 · see citing works

Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function

Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978 · see citing works

A human memory T cell subset with stem cell–like properties

Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · see citing works

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842 · see citing works

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · see citing works

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,812 · see citing works

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785 · see citing works

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646 · see citing works

Transcriptional control of effector and memory CD8+ T cell differentiation

Kaech, S. M., & Cui, W. (2012) · Nature Reviews Immunology · doi:10.1038/nri3307 · Cited by 1,628 · see citing works

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348 · see citing works

Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240 · see citing works

BSMAP: whole genome bisulfite sequence MAPping program

Xi, Y., & Li, W. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-232 · Cited by 1,216 · see citing works

TOX is a critical regulator of tumour-specific T cell differentiation

Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106 · see citing works

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · see citing works

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004 · see citing works

The epigenetic landscape of T cell exhaustion

Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986 · see citing works

Interleukin-10 determines viral clearance or persistence in vivo

Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 920 · see citing works

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 900 · see citing works

c-Jun overexpression in CAR T cells induces exhaustion resistance

Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · cited 2× · see citing works

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862 · see citing works

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

Imai, C., Mihara, K., Andreánsky, M., Nicholson, I., Pui, C., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 844 · see citing works

De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation

Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G. A. M., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 792 · see citing works

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547 · see citing works

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., Anibal, J., Sachs, A., Adebola, S. O., Gurusamy, D., et al. (2020) · Science · doi:10.1126/science.abb9847 · Cited by 541 · see citing works

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Heczey, A. A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A. G., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A. P., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535 · see citing works

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527 · see citing works

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Beatty, G. L., O’Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.029 · Cited by 515 · see citing works

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 504 · see citing works

Effector CD8 T cells dedifferentiate into long-lived memory cells

Youngblood, B., Hale, J. S., Kissick, H. T., Ahn, E., Xu, X., Wieland, A., Araki, K., West, E. E., Ghoneim, H. E., Fan, Y., et al. (2017) · Nature · doi:10.1038/nature25144 · Cited by 481 · see citing works

Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells

Liao, J., Karnik, R., Gu, H., Ziller, M. J., Clement, K., Tsankov, A. M., Akopian, V., Gifford, C. A., Donaghey, J., Galonska, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3258 · Cited by 470 · see citing works

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Guo, Y., Xie, Y., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 441 · see citing works

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

Youngblood, B., Oestreich, K. J., Ha, S., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 418 · see citing works

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M. R., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 408 · see citing works

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

Park, J. H., Geyer, M. B., & Brentjens, R. J. (2016) · Blood · doi:10.1182/blood-2016-02-629063 · Cited by 404 · see citing works

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Mueller, K. T., Maude, S. L., Porter, D. L., Frey, N. V., Wood, P. A., Han, X., Waldron, E. K., Chakraborty, A., Awasthi, R., Levine, B. L., et al. (2017) · Blood · doi:10.1182/blood-2017-06-786129 · Cited by 362 · see citing works

Detection of differentially methylated regions from whole-genome bisulfite sequencing data without replicates

Wu, H., Xu, T., Feng, H., Chen, L., Li, B., Yao, B., Qin, Z. S., Jin, P., & Conneely, K. N. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv715 · Cited by 350 · see citing works

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

Krenciute, G., Prinzing, B. L., Yi, Z., Wu, M.-F., Liu, H., Dotti, G., Balyasnikova, I. V., & Gottschalk, S. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0376 · Cited by 319 · see citing works

BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers

Roychoudhuri, R., Clever, D. C., Li, P., Wakabayashi, Y., Quinn, K. M., Klebanoff, C. A., Ji, Y., Sukumar, M., Eil, R. L., Yu, Z., et al. (2016) · Nature Immunology · doi:10.1038/ni.3441 · Cited by 317 · see citing works

MOABS: model based analysis of bisulfite sequencing data

Sun, D., Xi, Y., Rodriguez, B. A. T., Park, H. J., Tong, P., Meong, M., Goodell, M. A., & Li, W. (2014) · Genome biology · doi:10.1186/gb-2014-15-2-r38 · Cited by 299 · see citing works

Developmental plasticity allows outside-in immune responses by resident memory T cells

Fonseca, R., Beura, L. K., Quarnstrom, C. F., Ghoneim, H. E., Fan, Y., Zebley, C. C., Scott, M. C., Fares-Frederickson, N. J., Wijeyesinghe, S., Thompson, E. A., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0607-7 · Cited by 286 · see citing works

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

Chow, K. K. H., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N. C., Wu, M.-F., Liu, H., Kew, Y., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 241 · see citing works

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

Ghosh, A., Smith, M. M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., Gunset, G., Perna, F., Kreines, F. M., Levy, E. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4258 · Cited by 219 · see citing works

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215 · see citing works

Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ

Fujii, S., Shimizu, K., Shimizu, T., & Lotze, M. T. (2001) · Blood · doi:10.1182/blood.v98.7.2143 · Cited by 208 · see citing works

Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function

Scharer, C. D., Barwick, B. G., Youngblood, B., Ahmed, R., & Boss, J. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301395 · Cited by 207 · see citing works

Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells

Ahmed, N. M., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4309 · Cited by 192 · see citing works

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

Mata, M., Gerken, C. P., Nguyen, P., Krenciute, G., Spencer, D. M., & Gottschalk, S. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0263 · Cited by 180 · see citing works

CRIS.py: A Versatile and High-throughput Analysis Program for CRISPR-based Genome Editing

Connelly, J. P., & Pruett‐Miller, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-40896-w · Cited by 174 · see citing works

Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells

Youngblood, B., Noto, A., Porichis, F., Akondy, R. S., Ndhlovu, Z. M., Austin, J. W., Bordi, R., Procopio, F. A., Miura, T., Allen, T. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203161 · Cited by 169 · see citing works

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., Dotti, G., Wu, M.-F., Liu, H., Kenney, S. C., et al. (2011) · Blood · doi:10.1182/blood-2010-04-278218 · Cited by 165 · see citing works

Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis

Abdelsamed, H. A., Moustaki, A., Fan, Y., Dogra, P., Ghoneim, H. E., Zebley, C. C., Triplett, B. M., Sékaly, R., & Youngblood, B. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161760 · Cited by 147 · see citing works

Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia

Iacobucci, I., Li, Y., Roberts, K. G., Dobson, S. M., Kim, J. C., Payne-Turner, D., Harvey, R. C., Valentine, M. L., McCastlain, K., Easton, J. B., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.013 · Cited by 146 · see citing works

Transcriptional and Epigenetic Regulation of Effector and Memory CD8 T Cell Differentiation

Chen, Y., Zander, R., Khatun, A., Schauder, D., & Cui, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02826 · Cited by 146 · see citing works

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

Yi, Z., Prinzing, B. L., Cao, F., Gottschalk, S. M., & Krenciute, G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.009 · Cited by 123 · see citing works

Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes

Abdelsamed, H. A., Zebley, C. C., Nguyen, H., Rutishauser, R. L., Fan, Y., Ghoneim, H. E., Crawford, J. C., Alfei, F., Alli, S., Ribeiro, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0633-5 · Cited by 121 · see citing works

Pathway-Based Genomics Prediction using Generalized Elastic Net

Sokolov, A., Carlin, D. E., Paull, E., Baertsch, R., & Stuart, J. M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004790 · Cited by 108 · see citing works

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.-F., Liu, H., Dotti, G., Gottschalk, S. M., Metelitsa, L. S., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.025 · Cited by 107 · see citing works

Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media

Bauler, M. N., Roberts, J. K., Wu, C., Fan, B., Ferrara, F., Yip, B. H., Diao, S., Kim, Y., Moore, J., Zhou, S., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.011 · Cited by 102 · see citing works

Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion

Ahn, E., Youngblood, B., Lee, J., Lee, J., Sarkar, S., & Ahmed, R. (2016) · Journal of Virology · doi:10.1128/jvi.00798-16 · Cited by 95 · see citing works

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma

Krenciute, G., Krebs, S. S., Torres, D., Wu, M.-F., Liu, H., Dotti, G., Li, X., Lesniak, M. S., Balyasnikova, I. V., & Gottschalk, S. M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.199 · Cited by 90 · see citing works

Driving CAR T cell translation forward

Schultz, L. M., & Mackall, C. L. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2127 · Cited by 78 · see citing works

Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy

Zebley, C. C., Gottschalk, S. M., & Youngblood, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.008 · Cited by 69 · see citing works

Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells.

Youngblood, B., Wherry, E. J., & Ahmed, R. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834ddcf2 · Cited by 68 · see citing works

A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function

Lange, S., Sand, L. G. L., Bell, M., Patil, S. L., Langfitt, D., & Gottschalk, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0896 · Cited by 68 · see citing works

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies

Velasquez, M. P., Torres, D., Iwahori, K., Kakarla, S., Arber, C., Rodríguez-Cruz, T., Szöőr, Á., Bonifant, C. L., Gerken, C. P., Cooper, L. J. N., et al. (2016) · Scientific Reports · doi:10.1038/srep27130 · Cited by 58 · see citing works

Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity

Chan, W. K., Suwannasaen, D., Throm, R. E., Li, Y., Eldridge, P. W., Houston, J., Gray, J. T., Pui, C.-H., & Leung, W. H. (2014) · Leukemia · doi:10.1038/leu.2014.174 · Cited by 54 · see citing works

Dnmt3a regulates T-cell development and suppresses T-ALL transformation

Kramer, A. C., Kothari, A., Wilson, W. C., Celik, H., Nikitas, J., Mallaney, C., Ostrander, E. L., Eultgen, E., Martens, A., Valentine, M. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.89 · Cited by 53 · see citing works

Epigenetic Repression of Interleukin 2 Expression in Senescent CD4+T Cells During Chronic HIV Type 1 Infection

Nakayama‐Hosoya, K., Ishida, T., Youngblood, B., Nakamura, H., Hosoya, N., Koga, M., Koibuchi, T., Iwamoto, A., & Kawana‐Tachikawa, A. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu376 · Cited by 45 · see citing works

Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion

Tovy, A., Reyes, J. M., Gundry, M. C., Brunetti, L., Lee-Six, H., Petljak, M., Park, H. J., Guzman, A. G., Rosas, C., Jeffries, A. R., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.06.018 · Cited by 30 · see citing works

Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors

Chockley, P. J., Patil, S. L., & Gottschalk, S. M. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.04.010 · Cited by 20 · see citing works

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 673 · see citing works

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Albelda, S. Μ. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 535 · see citing works

T Cell Exhaustion

Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works

Epigenetic regulation of T cell exhaustion

Belk, J. A., Dániel, B., & Satpathy, A. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01224-z · Cited by 334 · see citing works

RASA2 ablation in T cells boosts antigen sensitivity and long-term function

Carnevale, J. C., Shifrut, E., Kale, N., Nyberg, W. A., Blaeschke, F., Chen, Y. Y., Li, Z., Bapat, S. P., Diolaiti, M. E., O’Leary, P. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05126-w · Cited by 236 · see citing works

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401361 · Cited by 220 · see citing works

CAR-T Therapies in Solid Tumors: Opportunities and Challenges

Guzman, G., Reed, M. R., Bielamowicz, K., Koss, B. S., & Rodriguez, A. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01380-x · Cited by 207 · see citing works

The Epigenetic Hallmarks of Cancer

Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 184 · see citing works

Clonal haematopoiesis and dysregulation of the immune system

Belizaire, R., Wong, W. J., Robinette, M. L., & Ebert, B. L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00843-3 · Cited by 161 · see citing works

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 157 · see citing works

Metabolic challenges and interventions in CAR T cell therapy

Peng, J.-J., Wang, L., Li, Z., Ku, C., & Ho, P. (2023) · Science Immunology · doi:10.1126/sciimmunol.abq3016 · Cited by 150 · see citing works

Methylation across the central dogma in health and diseases: new therapeutic strategies

Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 147 · see citing works

T cell dysfunction and therapeutic intervention in cancer

Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 142 · see citing works

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Lei, T., Wang, Y., Zhang, Y., Yang, Y., Cao, J., Huang, J., Chen, J., Chen, H., Zhang, J., wang, L., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02444-y · Cited by 141 · see citing works

Clonal hematopoiesis: Mutation-specific adaptation to environmental change

Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129 · see citing works

Epigenome editing technologies for discovery and medicine

McCutcheon, S. R., Rohm, D., Iglesias, N., & Gersbach, C. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02320-1 · Cited by 122 · see citing works

Chromatin remodellers as therapeutic targets

Malone, H. A., & Roberts, C. W. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00978-5 · Cited by 109 · see citing works

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Xia, X., Yang, Z., Lu, Q., Liu, Z., Wang, L., Du, J., Li, Y., Yang, D., & Wu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02079-8 · Cited by 109 · see citing works

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia

Zebley, C. C., Brown, C., Tian, M., Fan, Y., Alli, S., Boi, S. K., Galletti, G., Lugli, E., Langfitt, D. M., Métais, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110079 · Cited by 108 · see citing works

CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors

Reed, S. C., Croessmann, S., & Park, B. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2598 · Cited by 108 · see citing works

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., & Shi, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02032-9 · Cited by 104 · see citing works

CAR-T cells in solid tumors: Challenges and breakthroughs

Escobar, G., Berger, T. R., & Maus, M. V. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102353 · Cited by 104 · see citing works

Mechanisms of CAR T cell exhaustion and current counteraction strategies

Zhu, X., Li, Q., & Zhu, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1034257 · Cited by 101 · see citing works

Novel strategies for cancer immunotherapy: counter-immunoediting therapy

Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 98 · see citing works

Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy

Kang, T. G., Lan, X., Tian, M., Chen, H., Alli, S., Lim, S.-E., Bhatara, S., Vasandan, A. B., Ward, G., Bentivegna, S., et al. (2024) · Science · doi:10.1126/science.adl4492 · Cited by 98 · see citing works

Naturally occurring T cell mutations enhance engineered T cell therapies

Garcia, J. M., Daniels, J., Lee, Y., Zhu, I., Cheng, K., Liu, Q., Goodman, D. B., Burnett, C. E., Law, C., Thienpont, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07018-7 · Cited by 96 · see citing works

Disruption of <i>SUV39H1</i> -Mediated H3K9 Methylation Sustains CAR T-cell Function

Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1319 · Cited by 95 · see citing works

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 95 · see citing works

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM

Ζαννίκου, Μ., Duffy, J. T., Levine, R., Seblani, M. D., Liu, Q., Presser, A., Arrieta, V. A., Chen, C. J., Sonabend, A. M., Horbinski, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006239 · Cited by 92 · see citing works

Regulators of CD8+ T cell exhaustion

Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 90 · see citing works

Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion

Lamarche, C., Ward‐Hartstonge, K. A., Tian, M., Lin, D. T. S., Huang, Q. B., Brown, A., Edwards, K., Novakovsky, G., Qi, C. N., Kobor, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219086120 · Cited by 86 · see citing works

Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens

McCutcheon, S. R., Swartz, A. M., Brown, M. C., Barrera, A., Amador, C. M., Siklenka, K., Humayun, L. L., ter Weele, M. A., Isaacs, J. M., Reddy, T. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01554-0 · Cited by 86 · see citing works

Cellular and molecular waypoints along the path of T cell exhaustion

Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 84 · see citing works

Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells

Mai, D., Johnson, O., Reff, J., Fan, T., Scholler, J., Sheppard, N. C., & June, C. H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218632120 · Cited by 83 · see citing works

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence

Wei, W., Chen, Z., & Wang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512317 · Cited by 83 · see citing works

Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway

Zhu, M., Han, Y., Gu, T., Wang, R. Y., Si, X., Kong, D., Zhao, P., Wang, X., Li, J., Zhai, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114065 · Cited by 83 · see citing works

The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells

Baxter, A. E., Huang, H., Giles, J. R., Chen, Z., Wu, J. E., Drury, S., Tuite-Dalton, K. A., Park, S. L., Torres, L., Simone, B. W., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.008 · Cited by 81 · see citing works

Clonal hematopoiesis and inflammation – the perpetual cycle

Avagyan, S., & Zon, L. I. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.12.001 · Cited by 79 · see citing works

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 79 · see citing works

Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion

Battistello, E., Hixon, K., Comstock, D. E., Collings, C. K., Chen, X., Rodriguez-Hernaez, J., Lee, S., Cervantes, K. S., Hinkley, M. M., Ntatsoulis, K., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.02.026 · Cited by 74 · see citing works

Systematic profiling reveals betaine as an exercise mimetic for geroprotection

Geng, L., Ping, J., Wu, R., Yan, H., Zhang, H., Zhuang, Y., Ning, T., Wang, J., Liang, C., Zhang, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.001 · Cited by 73 · see citing works

<i>SUV39H1</i> Ablation Enhances Long-term CAR T Function in Solid Tumors

López-Cobo, S., Fuentealba, J. R., Gueguen, P., Bonté, P.-E., Tsalkitzi, K., Chacón, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1350 · Cited by 72 · see citing works

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors

Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 72 · see citing works

Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors

Ahn, T., Bae, E., & Seo, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.004 · Cited by 70 · see citing works

CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies

Huang, J., Huang, X., & Huang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019115 · Cited by 69 · see citing works

Modular pooled discovery of synthetic knockin sequences to program durable cell therapies

Blaeschke, F., Chen, Y. Y., Apathy, R., Dániel, B., Chen, A. Y., Chen, P. A., Sándor, K., Zhang, W., Li, Z., Mowery, C. T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.013 · Cited by 69 · see citing works

Impact of epigenetic reprogramming on antitumor immune responses in glioma

McClellan, B. L., Haase, S., Núñez, F. J., Alghamri, M. S., Dabaja, A. A., Lowenstein, P. R., & Castro, M. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163450 · Cited by 68 · see citing works

Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells

Glaser, V., Flugel, C., Kath, J., Du, W., Drosdek, V., Franke, C., Stein, M., Pruß, A., Schmueck-Henneresse, M., Volk, H.-D., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02928-7 · Cited by 65 · see citing works

Mechanisms of T cell exhaustion guiding next-generation immunotherapy

Zebley, C. C., & Youngblood, B. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.004 · Cited by 65 · see citing works

Fueling CARs: metabolic strategies to enhance CAR T-cell therapy

der Vreken, A. V., Vanderkerken, K., Bruyne, E. D., Veirman, K. D., Breckpot, K., & Menu, E. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00535-1 · Cited by 60 · see citing works

Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer

Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 60 · see citing works

The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy

Micevic, G., Bosenberg, M., & Yan, Q. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0784 · Cited by 59 · see citing works

Engineering chimeric antigen receptor T cells for solid tumour therapy

Liu, L., Qu, Y., Cheng, L., Yoon, C. W., He, P., Monther, A., Guo, T., Chittle, S. J., & Wang, Y. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1141 · Cited by 59 · see citing works

Optimizing the manufacturing and antitumour response of CAR T therapy

Liu, Y., Sperling, A. S., Smith, E. L., & Mooney, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00031-x · Cited by 59 · see citing works

Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement

Lan, X., Tian, M., Alli, S., Guy, C. S., Djekidel, M. N., Liu, X., Boi, S. K., Chowdhury, P. S., He, M.-H., Zehn, D., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01843-8 · Cited by 58 · see citing works

Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics

Zhong, F., Lin, Y., Zhao, L., Yang, C., Ye, Y., & Shen, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02292-0 · Cited by 57 · see citing works

Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy

Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 57 · see citing works

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 55 · see citing works

Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment

Guan, Q., Han, M., Guo, Q., Yan, F., Wang, M., Ning, Q., & Xi, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1204363 · Cited by 54 · see citing works

Integration of ζ-deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells

Kath, J., Franke, C., Drosdek, V., Du, W., Glaser, V., Fuster‐García, C., Stein, M., Zittel, T., Schulenberg, S., Porter, C. E., et al. (2024) · Blood · doi:10.1182/blood.2023020973 · Cited by 52 · see citing works

Regulatory T-cell therapy approaches

McCallion, O., Bilici, M., Hester, J., & Issa, F. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac078 · Cited by 50 · see citing works

IL-7R licenses a population of epigenetically poised memory CD8 + T cells with superior antitumor efficacy that are critical for melanoma memory

Micevic, G., Daniels, A., Karlsen, K. F., Park, K., Talty, R., McGeary, M. K., Mirza, H., Blackburn, H. N., Sefik, E., Cheung, J. F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2304319120 · Cited by 49 · see citing works

Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models

Talbot, L. J., Chabot, A., Ross, A. B., Beckett, A., Nguyen, P., Fleming, A. M., Chockley, P. J., Sheppard, H., Wang, J., Gottschalk, S. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3298 · Cited by 48 · see citing works

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Ali, A. M., & DiPersio, J. F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432799 · Cited by 47 · see citing works

Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma

Canedo, G. D. O., Roddie, C., & Amrolia, P. J. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013586 · Cited by 46 · see citing works

T cell-based cancer immunotherapy: opportunities and challenges

Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 46 · see citing works

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling

Bell, M. R., Lange, S., Sejdiu, B. I., Ibañez-Vega, J., Shi, H., Sun, X., Meng, X., Nguyen, P., Sutton, M. T., Wagner, J., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01143-w · Cited by 45 · see citing works

Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches

Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 44 · see citing works

Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy

Ottaviano, G., & Qasim, W. (2025) · Leukemia · doi:10.1038/s41375-025-02585-8 · Cited by 44 · see citing works

RNA Therapeutics for Improving CAR T-cell Safety and Efficacy

Schaible, P., Bethge, W. A., Lengerke, C., & Haraszti, R. Á. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2155 · Cited by 43 · see citing works

IL-4 drives exhaustion of CD8+ CART cells

Stewart, C. M., Siegler, E. L., Sakemura, R. L., Cox, M. J., Huynh, T., Kimball, B. L., Mai, L., Can, İ., Roman, C. M., Yun, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51978-3 · Cited by 43 · see citing works

Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

von Beck, K., von Beck, T. A., Ferrell, P. B., Bick, A. G., & Kishtagari, A. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00773-8 · Cited by 42 · see citing works

Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy

Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 42 · see citing works

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Moradi, V., Khodabandehloo, E., Alidadi, M., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1388475 · Cited by 42 · see citing works

Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects

Qin, H., Zhou, Z., Shi, R., Mai, Y., Xu, Y., Fu, P., Cheng, G., Zhang, Z., Chen, W., Chen, Y., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01701-6 · Cited by 41 · see citing works

Clonal hematopoiesis: Molecular and clinical implications

Kusne, Y. N., Xie, Z., & Patnaik, M. M. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106787 · Cited by 41 · see citing works

Tracing the development of CAR-T cell design: from concept to next-generation platforms

Alsaieedi, A., & Zaher, K. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615212 · Cited by 40 · see citing works

Developmental origins shape the paediatric cancer genome

Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 38 · see citing works

TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function

Dimitri, A. J., Baxter, A. E., Chen, G. M., Hopkins, C. R., Rouin, G. T., Huang, H., Kong, W., Holliday, C., Wiebking, V., Bartoszek, R. L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp9371 · Cited by 37 · see citing works

The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer

Zhang, J., Lei, F., & Tan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166128 · Cited by 36 · see citing works

Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 36 · see citing works

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

Liu, J., Jiao, X., Ma, D., Fang, Y., & Gao, Q. (2024) · Med · doi:10.1016/j.medj.2024.03.001 · Cited by 35 · see citing works

Epigenetic regulation of T cell exhaustion in cancer

Kang, T. G., Johnson, J. T., Zebley, C. C., & Youngblood, B. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00883-y · Cited by 35 · see citing works

Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction

Jung, I.-Y., Bartoszek, R. L., Rech, A. J., Collins, S. M., Ooi, S., Williams, E. F., Hopkins, C. R., Narayan, V., Haas, N. B., Frey, N. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1175 · Cited by 35 · see citing works

Single-cell analysis of acute lymphoblastic and lineage-ambiguous leukemia: approaches and molecular insights

Iacobucci, I., Witkowski, M. T., & Mullighan, C. G. (2022) · Blood · doi:10.1182/blood.2022016954 · Cited by 34 · see citing works

Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin’s lymphoma

Herzberg, C., Schiele, P., Walter, A. L., Hamm, F., Obermayer, B., Kath, J., Busch, D., Stroux, A., Frick, M., Penack, O., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010709 · Cited by 33 · see citing works

Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers

Pirouzbakht, M., Hamzeh, S., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01902-w · Cited by 33 · see citing works

Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome

Salz, L., Seitz, A., Schaefer, D., Franzen, J., Holzer, T., García-Prieto, C. A., Bürger, I., Hardt, O., Esteller, M., & Wagner, W. (2023) · Leukemia · doi:10.1038/s41375-023-01966-1 · Cited by 33 · see citing works

Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells

Qiu, F., Jiang, P., Zhang, G., An, J., Ruan, K., Lyu, X., Zhou, J., & Sheng, W. (2024) · Nature Communications · doi:10.1038/s41467-024-48607-4 · Cited by 32 · see citing works

Integrated epigenetic and genetic programming of primary human T cells

Goudy, L., Ha, A. S., Borah, A. A., Umhoefer, J. M., Chow, L., Tran, C., Winters, A., Talbot, A., Hernandez, R., Li, Z., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02856-w · Cited by 32 · see citing works

Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance

García-Robledo, J. E., Cabrera-Salcedo, S. C., Brandauer, A. M., Romano, F., Rengifo-Martinez, J., Toro-Pedroza, A., Hincapie, J. S. V., Ríos-Serna, L. J., Loukanov, A. R., Cardona, A. F., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1698442 · Cited by 32 · see citing works

Cytokine signaling in chimeric antigen receptor T-cell therapy

Kagoya, Y. (2023) · International Immunology · doi:10.1093/intimm/dxad033 · Cited by 31 · see citing works

CAR-engineered cell therapies: current understandings and future perspectives

Bayat, M., & Nahand, J. S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00401-4 · Cited by 31 · see citing works

New target DDR1: A “double-edged sword” in solid tumors

Tian, Y., Bai, F., & Zhang, D. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188829 · Cited by 31 · see citing works

Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance

Qin, Y., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053120 · Cited by 31 · see citing works

Clonal hematopoiesis and differential outcomes after immune checkpoint blockade

Hsiehchen, D., Sfreddo, H. J., Zhao, K., Han, C. Y., & Morris, L. G. T. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.024 · Cited by 30 · see citing works

Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface

Buttigieg, M. M., & Rauh, M. J. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00132 · Cited by 29 · see citing works

GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells

Ibañez-Vega, J., Hebbar, N., Thanekar, U., Yi, Z., Houke, H., Ward, M. B., Nevitt, C. D., Tian, L., Mack, S. C., Sheppard, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101297 · Cited by 29 · see citing works

DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells

Ramabadran, R., Wang, J. H., Reyes, J. M., Guzman, A. G., Gupta, S., Rosas, C., Brunetti, L., Gundry, M. C., Tovy, A., Long, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01109-9 · Cited by 29 · see citing works

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29 · see citing works

De novo DNA methylation programs regulate CAR T-cell exhaustion

Zebley, C. C., Petersen, C. T., Prinzing, B. L., Bell, M. R., Fan, Y., Crawford, J. C., Houke, H., Haydar, D., Yi, Z., Nguyen, P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.204.supp.246.5 · Cited by 5 · see citing works

De novo DNA methylation programs regulate T cell exhaustion and limit T cell-based immunotherapies

Youngblood, B., Ghoneim, H. E., Abdelsamed, H. A., Moustaki, A., Fan, Y., Crawford, J. C., Thomas, P. G., Stewart, E. S., & Federico, S. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.202.supp.134.14 · Cited by 3 · see citing works

CAR T cells need a pitstop to win the race

Zebley, C. C., & Youngblood, B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.011 · Cited by 5 · see citing works

Abstract 61: Transient "rest" reinvigorates exhausted CAR T cells via epigenetic remodeling

Weber, E. W., & Mackall, C. L. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-61

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Dániel, B., Klysz, D. D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 629 · see citing works